THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Dr. Josef Scheiber, Founder & Managing DirectorBioVariance employs medical and multi-omics data analysis to study biomarkers and comparatively deduce the optimal diagnostics and treatment needed for each medical condition. Leveraging machine learning algorithms, the company detects the onset of diseases at the molecular level. BioVariance has built mathematical models that are trained with the data sets obtained from patients to understand the variance in diseases and suitably arrive at the cure.
Pharma companies access BioVariance’s complex algorithms to study bioinformatics and genomic data for therapeutic care. As the data analysis firm offers a cloud-based, highly-scalable analytics platform enabled with an intuitive web interface, the pharma companies can innovate personalized treatment with great ease and flexibility.
BioVariance not only deduces the appropriate medication for patients but also supports preventive care. The company accelerates medical data analysis by utilizing publicly available metabolome, transcriptome, and genome data available in the multi-omics space. It feeds disease-specific therapeutic data into its machine learning engine consistently for accurate results. With such an approach, doctors and other medical professionals can diagnose the disease quickly and efficiently. A case in point: BioVariance collaborated with a pharma company that wanted to predict the onset of a particular disease as early as possible using biomarkers. By aggregating data through the analysis of saliva or blood samples, BioVariance distinguished biomarker differences between affected patients and healthy people, enabling the client to predict the outbreak of diseases and take preventive measures accordingly.
We support the healthcare, pharmaceutical, and biotechnology sectors by combining individual treatment recommendations with monitoring capabilities
BioVariance ensures that therapeutic procedures are improved to enhance medical treatment further. The company goes a step further in personalizing care through its Pillbox application for permanent monitoring and control of therapy. The application notifies patients to take medications at regular intervals as prescribed and increases the safety of therapeutic procedures through relevant ‘documentation aids’ that support the course of treatments.
Treading on the success of its personalized care and backed by a well-structured team of subject matter experts from software, data science, and clinical areas, BioVariance aspires to expand its global footprint. In the near future, the company can be expected to provide patients the access to precision medicine and relevant therapeutic processes. Since applying algorithms for therapeutic care is still unregulated, BioVariance aims to standardize its processes and make it available to pharma companies and physicians worldwide.
Company
BioVariance
Management
Dr. Josef Scheiber, Founder & Managing Director
Description
BioVariance brings to the table a unique approach to personalize therapeutic and medicinal care. The company assists pharmaceutical organizations, healthcare firms, and biotechnology companies in providing individualized care through advanced biomarker analytics and inventive software. By feeding pathological data previously obtained from patients to advanced machine learning algorithms, BioVariable deduces the optimal diagnostics and treatment needed for each medical condition. The company goes a step further in personalizing care through its Pillbox application for permanent monitoring and control of therapy. Collectively, BioVariance’s expertise allow medical institutions to understand the onset of disease in addition to crafting individual therapeutic procedures
Bio-Variance is a 2013 founded bioinformatics company from Waldsassen. The 19 employees analyze and interpret complex biomedical data. They identify biological signatures of patients. Among other things, this serves for the individual adaptation of the medication, for example for oncological or psychiatric indications.
"This has turned out beautifully," said Scheiber on request of Oberpfalz-Medien about the cooperation and reveals that the first contact with the partners was created by chance - at a symposium in Munich. There, Scheiber had attracted attention with a critical statement on data protection in the health sector.